AUTONOMIX MEDICAL INC (AMIX)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$2.42-3.20%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge AUTONOMIX MEDICAL INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.64
Annual ending 2027-03-31
Revenue	—	0
EPS	—	-8.6
Annual ending 2028-03-31
Revenue	—	900,000
EPS	—

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
secure funding through private placements	The company raised funds in private placements in 2025.	Under Pressure	failure to raise capital triggers delisting risk	Qualitative: Delisting notice active, no new capital raised Nasdaq deficiency letter for sub-$1.00 price. Warrant inducement and reverse split signal financial distress rather than successful capital raising. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-03-31 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 1
2026-07-25	Unavailable	Unavailable	1 / 1
2026-07-26	Unavailable	Unavailable	1 / 1
2026-07-27	Unavailable	Unavailable	1 / 1
2026-07-28	Unavailable	Unavailable	1 / 1
2026-07-29	Unavailable	Unavailable

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

secure funding through private placementsPublished status: Under Pressure
reduce net loss per shareDirect metric needs a verified mapping
maintain Nasdaq listing standardsPublished status: Under Pressure

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.9%Typical daily move · historical

Downside history

-90.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

AUTONOMIX MEDICAL INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

AMIX is a high-risk, loss-making growth and development story, not an established compounder. The thesis is still intact, but confidence is low and recent evidence of progress remains limited.

What's priced into AUTONOMIX MEDICAL INC

The evidence snapshot gives no valuation measure or direct account of market expectations, so it is not possible to say whether AMIX looks cheap, fair, or expensive versus peers. The main known expectation is that the company can make progress on clinical development and partnerships while controlling losses, but the evidence does not show those efforts producing clear financial results yet.

What the fundamentals likely do

Over the multi-year view, losses may narrow if management continues improving operating performance, but the company remains loss-making and its cash-burn control is rated behind. Near term, erratic earnings and smaller-cap risk make the next results uncertain; management has also emphasized capital allocation, security-holder rights, and early-stage clinical and partnership work.

What AUTONOMIX MEDICAL INC hinges on

The thesis depends on whether loss control improves and clinical development or partnerships show measurable progress. In the near term, weakening job growth could increase recession concerns, while continued strong results from Healthcare bellwethers such as ABT, MDT, and SYK could support the sector backdrop; misses or weaker guidance could remove that support.

Bottom line

For the next 1 to 3 years, AMIX has an intact but low-confidence thesis: improving losses and progress in development are possible, while execution risk and uncertain sector conditions remain substantial. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

2026-07-30	Unavailable	Unavailable	2 / 2

2026-07-31	Unavailable	Unavailable	2 / 2

2026-08-01	Unavailable	Unavailable	2 / 2

2026-08-02	Unavailable	Unavailable	2 / 2

2026-08-03	Unavailable	Unavailable	2 / 2

2026-08-04	Unavailable	Unavailable	2 / 2

2026-08-05	Unavailable	Unavailable	2 / 2

2026-08-06	Unavailable	Unavailable	2 / 2

2026-08-07	Unavailable	Unavailable	1 / 1

2026-08-08	Unavailable	Unavailable	2 / 2

2026-08-09	Unavailable	Unavailable	2 / 2

2026-08-10	Unavailable	Unavailable	2 / 2

2026-08-11	Unavailable	Unavailable	1 / 1

2026-08-12	Unavailable	Unavailable	2 / 2

2026-08-13	Unavailable	Unavailable	2 / 2

2026-08-14	Unavailable	Unavailable	1 / 1

2026-08-15	Unavailable	Unavailable	1 / 1

2026-08-16	Unavailable	Unavailable	1 / 1

2026-08-17	Unavailable	Unavailable	1 / 1

2026-08-18	Unavailable	Unavailable	1 / 1

2026-08-19	Unavailable	Unavailable	1 / 1

2026-08-20	Unavailable	Unavailable	1 / 1

2026-08-21	Unavailable	Unavailable	1 / 1

2026-08-22	Unavailable	Unavailable	1 / 1

2026-08-23	Unavailable	Unavailable	1 / 1

2026-08-24	Unavailable	Unavailable	1 / 1

2026-08-25	Unavailable	Unavailable	1 / 1

2026-08-26	Unavailable	Unavailable	1 / 1

2026-08-27	Unavailable	Unavailable	1 / 1

2026-08-28	Unavailable	Unavailable	1 / 1

2026-08-29	Unavailable	Unavailable	1 / 1

2026-08-30	Unavailable	Unavailable	1 / 1

2026-08-31	Unavailable	Unavailable	1 / 1

2026-09-01	Unavailable	Unavailable	1 / 1

2026-09-02	Unavailable	Unavailable	1 / 1

2026-09-03	Unavailable	Unavailable	1 / 1

2026-09-04	Unavailable	Unavailable	1 / 1

2026-09-05	Unavailable	Unavailable	1 / 1

2026-09-06	Unavailable	Unavailable	1 / 1

2026-09-07	Unavailable	Unavailable	1 / 1

2026-09-08	Unavailable	Unavailable	1 / 1

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	2	0	0
2026-06-01	2	0	0
2026-07-01	2	0	0
2026-08-01	2	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

What could strengthen or challenge AUTONOMIX MEDICAL INC’s outlook?

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

AUTONOMIX MEDICAL INC outlook in detail

What kind of bet this is

What's priced into AUTONOMIX MEDICAL INC

What the fundamentals likely do

What AUTONOMIX MEDICAL INC hinges on

Bottom line

Analyst view

Price-target changes

Bottom line